News
Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis
Data to Date Support Results From Long-Term Phase 3 Study
NEW YORK, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced preliminary, unaudited data....
Novavax Reports Third-Quarter 2013 Financial Results
ROCKVILLE, Md., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of....
Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus...
Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney....
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus...
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney....
Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013
ROCKVILLE, Md., Oct. 30, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today that it will host a conference call and live webcast to report its third quarter 2013 financial....
ACTIVITE DU TROISIEME TRIMESTRE 2013
ACTIVITE DU TROISIEME TRIMESTRE 2013
(Données non auditées)
ACTIVITE CUMULEE A FIN SEPTEMBRE 2013
en milliers d'euros
2012
2013
Var. taux courant 2013/2012
Var. taux constant....
ACTIVITY IN THE THIRD QUARTER OF 2013
ACTIVITY IN THE THIRD QUARTER OF 2013
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2013
thousands of euros
2012
2013
Variation at current exchange....
Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa
Study Conducted by Development Partner R-Tech Ueno and Majority-Funded by Japan Science and Technology Agency (JST)
BETHESDA, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Sucampo AG, a subsidiary....
Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex(TM) New Drug Application
NEW YORK, Oct. 21, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee....
EnWave startet Moon Cheese® durch NutraDried LLP
Die EnWave Corporation gab am 17 Oktober 2013 bekannt, dass NutraDried LLP eine Partnerschaft mit Lucid Capital Management begonnen hat, die offiziell mit dem Start von Moon Cheese®, die durch EnWave´s
Keryx Biopharmaceuticals' Zerenex(TM) (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013
NEW YORK, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that abstracts highlighting Zerenex™ (ferric citrate coordination complex), the....
Formulaire de déclaration mensuelle des droits de vote Septembre 2013
Le 8 octobre 2013
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex(TM) New Drug Application
NEW YORK, Oct. 8, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that its New Drug Application (NDA) for Zerenex™ (ferric citrate coordination complex)....
Novavax Initiates Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate
ROCKVILLE, Md., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that enrollment has begun in a Phase 2 dose-confirmatory clinical trial of its respiratory....
Keryx Biopharmaceuticals, Inc. Announces Appointment of Daniel P. Regan to Board of Directors
Former Global General Manager, Senior Vice President of the Renal Franchise at Genzyme (Sanofi) Brings Key Renal Commercialization Expertise to Keryx
NEW YORK, Oct. 4, 2013 (GLOBE NEWSWIRE)....
Keryx Biopharmaceuticals Announces Appointment of Douglass H. Laidlaw, Ph.D., as Director, Medical Affairs
Formerly National Director, Medical Science Liaisons of the Renal Division at Genzyme/Sanofi
NEW YORK, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a....
Novavax Completes 100 Million USD Public Offering of Common Stock
ROCKVILLE, Md., Sept. 27, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced the closing of its previously announced underwritten public offering of 31,846,950 shares of its....
Novavax to Initiate Seasonal and Pandemic Influenza Trials in Collaboration With BARDA
Quadrivalent Seasonal Influenza Clinical Trial to start in 1Q2014
Pandemic Influenza Clinical Trial to start in the U.S. in 1H2014
Proprietary Adjuvant Matrix-M to be used in the....
Novavax Prices Public Offering of Common Stock
ROCKVILLE, Md., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it has priced an underwritten public offering of 27,693,000 shares of common stock at a....
GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne Muscular Dystrophy
LONDON and LEIDEN, Netherlands, Sept. 20, 2013 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Prosensa today announced that GSK's Phase III clinical study of drisapersen, an investigational....
EnWave unterzeichnet weiteres Kooperations- und Lizenzabkommen
EnWave gab bekannt, dass man ein weiteres Kooperationsabkommen mit einem schwergewichtigen Partner unterzeichnen konnte. Europas Marktführer in der vFleischerarbeitung, Campofrio Food Group beabsichtigt
Novavax to Host an Analyst and Investor Update Call With Webcast
ROCKVILLE, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine....
Novavax Highlights Positive Results From Partner's Clinical Trial of Vaccine Using Matrix-M(TM)
Genocea Biosciences' Herpes Simplex Therapeutic Vaccine uses Matrix-M adjuvant
Phase 1/2A U.S.-based clinical trial enrolled 143 volunteers with moderate-to-severe HSV-2
Two highest....
Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology
BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Sucampo AG ("SAG"), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), announced today that it will....
ICAAC Presentations Highlight Potential Protective Effects of Novavax' RSV Vaccine Candidate
ROCKVILLE, Md., Sept. 11, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine....